Effects of Coenzyme Q10 on muscular dystrophies and neurogenic atrophies.

January 28, 2003

Folkers K ; Simonsen R

Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular

dystrophies and neurogenic atrophies. Coenzyme Q10 (vitamin Q10) is

biosynthesized in the human body and is functional in bioenergetics,

anti-oxidation reactions, and in growth control, etc. It is indispensable to

health and survival. The first double-blind trial was with twelve patients,

ranging from 7-69 years of age, having diseases including the Duchenne, Becker,

and the limb-girdle dystrophies, myotonic dystrophy. Charcot-Marie-Tooth

disease, and the Welander disease. The control coenzyme Q10 (CoQ10) blood level

was low and ranged from 0.5-0.84 microgram/ml. They were treated for three

months with 100 mg daily of CoQ10 and a matching placebo. The second

double-blind trial was similar with fifteen patients having the same categories

of disease. Since cardiac disease is established to be associated with these

muscle diseases, cardiac function was blindly monitored, and not one mistake was

made in assigning CoQ10 and placebo to the patients in both trials. Definitely

improved physical performance was recorded. In retrospect, a dosage of 100 mg

was too low although effective and safe. Patients suffering from these muscle

dystrophies and the like, should be treated with vitamin Q10 indefinitely.

Biochim Biophys Acta 1995 May 24;1271(1):281-6

Gettingwell- / Vitamins, Herbs, Aminos, etc.

To , e-mail to: Gettingwell-

Or, go to our group site: Gettingwell

Mail Plus - Powerful. Affordable. Sign up now

Recommended Posts